Free tool
FAERS Monitor: Aurlumyn
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217933 or its brand name (Aurlumyn, Iloprost). Reports on generic versions are filed under their own applications.
Reports
932
Serious
880
94% of reports
Hospitalization
381
Death reported
286
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective122
- death77
- off label use77
- dyspnoea71
- condition aggravated66
- right ventricular failure64
- pulmonary arterial hypertension59
- hypotension52
- pulmonary hypertension41
- headache38
- pneumonia38
- maternal exposure during pregnancy37
- sepsis36
- cardiac failure35
- premature baby35
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 8 |
| 2006 | 4 |
| 2007 | 15 |
| 2008 | 15 |
| 2009 | 21 |
| 2010 | 24 |
| 2011 | 15 |
| 2012 | 13 |
| 2013 | 17 |
| 2014 | 24 |
| 2015 | 30 |
| 2016 | 33 |
| 2017 | 43 |
| 2018 | 76 |
| 2019 | 92 |
| 2020 | 87 |
| 2021 | 80 |
| 2022 | 40 |
| 2023 | 69 |
| 2024 | 65 |
| 2025 | 104 |
| 2026 | 54 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,227 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| right ventricular failureSignal | 64 | 208.0 | 164.0 | 12,863 |
| pulmonary arterial hypertensionSignal | 59 | 92.3 | 72.0 | 5,217 |
| pulmonary hypertensionSignal | 41 | 44.5 | 33.0 | 1,698 |
| premature babySignal | 35 | 26.3 | 19.0 | 826 |
| cardiac failureSignal | 35 | 9.8 | 7.1 | 270 |
| maternal exposure during pregnancySignal | 37 | 9.4 | 6.8 | 269 |
| sepsisSignal | 36 | 7.3 | 5.3 | 190 |
| hypotensionSignal | 52 | 5.9 | 4.5 | 206 |
| condition aggravatedSignal | 66 | 4.9 | 3.9 | 204 |
| dyspnoeaSignal | 71 | 2.8 | 2.3 | 85 |
| pneumoniaSignal | 38 | 2.6 | 1.9 | 38 |
| drug ineffectiveSignal | 122 | 2.1 | 1.8 | 73 |
| deathSignal | 77 | 2.0 | 1.6 | 40 |
| off label use | 77 | 2.0 | 1.6 | 38 |
| headache | 38 | 1.4 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.